The SCRUM-Japan MONSTAR-SCREEN consortium is a nationwide molecular profiling project employing artificial intelligence–driven multi-omics analyses for patients with advanced malignancies, aiming to develop novel therapeutics and diagnostics and deliver effective drugs to patients. Concurrently, studies assessing molecular residual disease–based precision medicine for resectable solid tumors, including CIRCULATE-Japan, are ongoing. The substantial data generated by these platforms are stored within a state-of-the-art supercomputing infrastructure, VAPOR CONE. Since 2015, our project has registered over 24,000 patients as of December 2023. Among 16,144 patients with advanced solid tumors enrolled in MONSTAR-SCREEN projects, 5.0% participated in matched clinical trials, demonstrating a 29.2% objective response rate and 14.8-month median survival (95% confidence interval, 13.4—16.3), for patients treated in the matched clinical trials. Notably, patients who received matched therapy demonstrated significantly prolonged overall survival compared with those who did not (hazard ratio 0.77; 95% confidence interval, 0.71—0.83).

中文翻译：

---

SCRUM-MONSTAR 癌症组学生态系统：努力实现精准医学的巨大飞跃


SCRUM-Japan MONSTAR-SCREEN 联盟是一个全国性的分子分析项目，采用人工智能驱动的多组学分析来治疗晚期恶性肿瘤患者，旨在开发新的治疗方法和诊断方法，并向患者提供有效的药物。与此同时，评估基于分子残留疾病的可切除实体瘤精准医学的研究（包括 CIRCULATE-Japan）正在进行中。这些平台生成的大量数据存储在最先进的超级计算基础设施 VAPOR CONE 中。自2015年以来，截至2023年12月，我们的项目已注册超过24,000名患者。在MONSTAR-SCREEN项目注册的16,144名晚期实体瘤患者中，5.0%参与了匹配的临床试验，客观缓解率为29.2%，中位生存期为14.8个月（95% 置信区间，13.4-16.3），对于在匹配的临床试验中接受治疗的患者。值得注意的是，与未接受匹配治疗的患者相比，接受匹配治疗的患者总生存期显着延长（风险比 0.77；95% 置信区间，0.71-0.83）。